GenSight Biologics S.A. (GSGTF)
OTCMKTS · Delayed Price · Currency is USD
0.2400
-0.0800 (-25.00%)
At close: Dec 31, 2024
GenSight Biologics Employees
GenSight Biologics had 16 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
16
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$169,855
Profits / Employee
-$905,956
Market Cap
24.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 0 | - |
| Dec 31, 2023 | 16 | -29 | -64.44% |
| Dec 31, 2022 | 45 | 7 | 18.42% |
| Dec 31, 2021 | 38 | 13 | 52.00% |
| Dec 31, 2020 | 25 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Endo, Inc. | 3,116 |
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
GenSight Biologics News
- 16 days ago - GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy - Business Wire
- 24 days ago - GenSight Biologics Reports Cash Position as of June 30, 2025 - Business Wire
- 7 weeks ago - GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France - Business Wire
- 2 months ago - GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025 - Business Wire
- 3 months ago - GenSight Biologics Annual General Meeting on May 13, 2025 - Business Wire
- 4 months ago - GenSight Biologics Announces the Filing of its 2024 Universal Registration Document - Business Wire
- 4 months ago - GenSight Biologics Reports Cash Position as of March 31, 2025, and Provides Business Update - Business Wire
- 4 months ago - GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates - Business Wire